Apr 3, 2020
COVID-19 Response
The current pandemic is a stark reminder to us all of the importance of our work and its potential impact.
Recent clinical data has shown that >50 per cent of hospitalised COVID-19 patients develop cytokine storm syndromes, and that these are a major driver of mortality.
The treatment of cytokine storms is one of the areas we are targeting with our magnetic blood filtration technology, which could be used to remove of IL-6, a major inflammatory cytokine which drives dysregulated immune responses. While we are not yet ready to trial this on humans, the current pandemic is extra motivation for us to work even harder on our technology in order to make it available to the world as soon as we can. The current pandemic is a stark reminder to us all of the importance of our work and its potential impact.
In the meantime, we are trying to support the local community by offering access to our 3D printers and sending spare PPE gear to local hospitals. Our international team have also translated the ViralKindness self-isolating postcards, which we are spreading via our social media channels. It is now available in French, Italian, German, Russian, Gaeilge, Spanish, and Catalan!
Help us spread #viralkindness: https://www.linkedin.com/posts/medisieve-limited_viralkindness-coronavirus-stayhomesavelives-activity-6648169217264758784-NnOl
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
